Institutional Career Development Core

机构职业发展核心

基本信息

项目摘要

The goal for our proposed KL2 Mentored Career Development Award Program is to maintain excellence and mentorship program that imparts the skills essential to conduct clinical and translational science in the era of interdisciplinary team science, precision medicine (PM), big data, and implementation science. At Columbia University Irving Medical Center (CUIMC), the KL2 program operates across schools, departments, and divisions as the only institution- wide disease-agnostic career development program in clinical and translational research. The Irving Institute's translational workforce development (TWD) of clinician and non-clinician scientists is centered in TRANSFORM (TRaining And Nurturing Scholars For Research that is Multidisciplinary), which oversees the Institutional Career Development Core (KL2 Mentored Career Development Award Program). The goal is to recruit individuals who conduct cutting edge and clinically relevant research regardless of the disease focus. Recruitment will focus on investigators from diverse backgrounds with research or health professional doctorates in medicine, surgery, nursing, dentistry, public health, psychiatry, arts and sciences, and engineering. The KL2 program will promote career development, translational capabilities, and collaborative and entrepreneurial skills of junior faculty from diverse disciplines who have recently finished research or health professional doctoral training. KL2 graduates will receive excellent and extensive career mentoring, and gain expertise in advanced clinical and translational research methods and comprehensive experimental approaches. This mentoring and training will allow KL2 scholars to compete more effectively for external funding, enhance their effective participation in interdisciplinary teams, and contribute to prevention and treatment of diseases through clinical and translational research. Our KL2 graduates will also be able to pay forward these skills through training and mentorship of the next generation of scientists. As such, the Specific Aims are: Aim 1. To continue our successful and innovative KL2 career development program and develop new programs to enhance the ability of our KL2 scholars to engage in and lead interdisciplinary team science and translate new discoveries to benefit our patients and communities. Aim 2. To demonstrate the effectiveness of the KL2 program through continuous comprehensive and systematic evaluation and quality improvement using key metrics, including Common Metrics, to optimize the impact of our educational and workforce development programs. Aim 3. To accelerate the dissemination of our training approaches to our partners at Columbia University (CU), the regional tri-state consortium (TriCon) of Clinical and Translational Science Award (CTSA) Program hubs and network, and the clinical and translational while enhancing and innovating our successful junior faculty training field at large.
我们提出的 KL2 指导职业发展奖励计划的目标是保持卓越 和导师计划,传授在跨学科团队科学、精准医学(PM)、大数据和实施科学时代进行临床和转化科学所必需的技能。在哥伦比亚大学欧文医学中心 (CUIMC),KL2 项目作为唯一的机构跨学校、院系和部门运作—— 临床和转化研究领域广泛的与疾病无关的职业发展计划。欧文 研究所的临床医生和非临床科学家的转化劳动力发展(TWD)集中于 TRANSFORM(培训和培养多学科研究学者),负责监督 机构职业发展核心(KL2 指导职业发展奖励计划)。目标是 招募进行前沿和临床相关研究的人员,无论疾病如何 重点。招聘将重点关注来自不同背景的研究人员或健康专业人士 医学、外科、护理、牙科、公共卫生、精神病学、艺术和科学博士学位,以及 工程。 KL2 计划将促进职业发展、翻译能力以及协作和 最近完成研究或健康的来自不同学科的初级教师的创业技能 专业博士培养。 KL2毕业生将获得优秀和广泛的职业指导,并获得 先进的临床和转化研究方法以及综合实验方法的专业知识。 这种指导和培训将使 KL2 学者能够更有效地竞争外部资金,增强 他们有效参与跨学科团队,为疾病的预防和治疗做出贡献 通过临床和转化研究。我们的 KL2 毕业生也将能够通过以下方式传授这些技能 下一代科学家的培训和指导。因此,具体目标是: 目标 1. 继续 我们成功且创新的 KL2 职业发展计划,并开发新计划来增强 我们的 KL2 学者参与和领导跨学科团队科学并将新发现转化为 造福我们的患者和社区。目标 2. 通过以下方式展示 KL2 计划的有效性: 使用关键指标进行持续全面、系统的评估和质量改进,包括 通用指标,以优化我们的教育和劳动力发展计划的影响。目标 3. 至 加速向哥伦比亚大学 (CU) 的合作伙伴传播我们的培训方法 三州联盟 (TriCon) 临床和转化科学奖 (CTSA) 项目中心和网络, 以及临床和转化,同时加强和创新我们成功的初级教师培训领域。

项目成果

期刊论文数量(56)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The coeliac stomach: gastritis in patients with coeliac disease.
In Reply: Spontaneous MAOI hypertensive reaction, not likely armodafinil - tranylcypromine interaction.
答复:自发性 MAOI 高血压反应,不太可能是阿莫达非尼 - 反苯环丙明相互作用。
Long-term outcomes of mesial temporal laser interstitial thermal therapy for drug-resistant epilepsy and subsequent surgery for seizure recurrence: a multi-centre cohort study.
颞内侧激光间质热疗治疗耐药性癫痫和随后手术治疗癫痫复发的长期结果:一项多中心队列研究。
  • DOI:
    10.1136/jnnp-2022-330979
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Youngerman,BrettE;Banu,MateiA;Khan,Farhan;McKhann,GuyM;Schevon,CatherineA;Jagid,JonathanR;Cajigas,Iahn;Theodotou,ChristianB;Ko,Andrew;Buckley,Robert;Ojemann,JeffreyG;Miller,JohnW;Laxton,AdrianW;Couture,DanielE;Popli,
  • 通讯作者:
    Popli,
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
比较接受新辅助化疗与初次细胞减灭术治疗的老年卵巢癌患者的生存率:通过机器学习减少偏差。
  • DOI:
    10.1016/j.ygyno.2024.03.016
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    Huang,Yongmei;Rauh-Hain,JAlejandro;McCoy,ThomasH;Hou,JuneY;Hillyer,Grace;Ferris,JenniferS;Hershman,Dawn;Wright,JasonD;Melamed,Alexander
  • 通讯作者:
    Melamed,Alexander
Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease.
  • DOI:
    10.1016/j.jhep.2015.01.013
  • 发表时间:
    2015-06
  • 期刊:
  • 影响因子:
    25.7
  • 作者:
    Reilly, Norelle R.;Lebwohl, Benjamin;Hultcrantz, Rolf;Green, Peter H. R.;Ludvigsson, Jonas F.
  • 通讯作者:
    Ludvigsson, Jonas F.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEANINE M. GENKINGER其他文献

JEANINE M. GENKINGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEANINE M. GENKINGER', 18)}}的其他基金

Coordinating Center for the Program on the Origins of Gastroesophageal Cancers
胃食管癌起源项目协调中心
  • 批准号:
    10506036
  • 财政年份:
    2022
  • 资助金额:
    $ 139.76万
  • 项目类别:
Coordinating Center for the Program on the Origins of Gastroesophageal Cancers
胃食管癌起源项目协调中心
  • 批准号:
    10698096
  • 财政年份:
    2022
  • 资助金额:
    $ 139.76万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    10349089
  • 财政年份:
    2016
  • 资助金额:
    $ 139.76万
  • 项目类别:
Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI
通过 WHI 中的表观遗传因素早期发现卵巢癌
  • 批准号:
    9240606
  • 财政年份:
    2016
  • 资助金额:
    $ 139.76万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    10439919
  • 财政年份:
    2016
  • 资助金额:
    $ 139.76万
  • 项目类别:
Dietary Factors and Risk of Pancreatic Cancer in a Pooled Analysis
汇总分析中的饮食因素和胰腺癌风险
  • 批准号:
    7862588
  • 财政年份:
    2009
  • 资助金额:
    $ 139.76万
  • 项目类别:
Dietary Factors and Risk of Pancreatic Cancer in a Pooled Analysis
汇总分析中的饮食因素和胰腺癌风险
  • 批准号:
    8013479
  • 财政年份:
    2009
  • 资助金额:
    $ 139.76万
  • 项目类别:
Dietary Factors and Risk of Pancreatic Cancer in a Pooled Analysis
汇总分析中的饮食因素和胰腺癌风险
  • 批准号:
    7663516
  • 财政年份:
    2009
  • 资助金额:
    $ 139.76万
  • 项目类别:

相似国自然基金

企业绩效评价的DEA-Benchmarking方法及动态博弈研究
  • 批准号:
    70571028
  • 批准年份:
    2005
  • 资助金额:
    16.5 万元
  • 项目类别:
    面上项目

相似海外基金

An innovative EDI data, insights & peer benchmarking platform enabling global business leaders to build data-led EDI strategies, plans and budgets.
创新的 EDI 数据、见解
  • 批准号:
    10100319
  • 财政年份:
    2024
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Collaborative R&D
BioSynth Trust: Developing understanding and confidence in flow cytometry benchmarking synthetic datasets to improve clinical and cell therapy diagnos
BioSynth Trust:发展对流式细胞仪基准合成数据集的理解和信心,以改善临床和细胞治疗诊断
  • 批准号:
    2796588
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Studentship
Elements: CausalBench: A Cyberinfrastructure for Causal-Learning Benchmarking for Efficacy, Reproducibility, and Scientific Collaboration
要素:CausalBench:用于因果学习基准测试的网络基础设施,以实现有效性、可重复性和科学协作
  • 批准号:
    2311716
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Standard Grant
Benchmarking collisional rates and hot electron transport in high-intensity laser-matter interaction
高强度激光-物质相互作用中碰撞率和热电子传输的基准测试
  • 批准号:
    2892813
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Studentship
Collaborative Research: SHF: Medium: A Comprehensive Modeling Framework for Cross-Layer Benchmarking of In-Memory Computing Fabrics: From Devices to Applications
协作研究:SHF:Medium:内存计算结构跨层基准测试的综合建模框架:从设备到应用程序
  • 批准号:
    2347024
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Standard Grant
Collaborative Research: BeeHive: A Cross-Problem Benchmarking Framework for Network Biology
合作研究:BeeHive:网络生物学的跨问题基准框架
  • 批准号:
    2233969
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Continuing Grant
FET: Medium: Quantum Algorithms, Complexity, Testing and Benchmarking
FET:中:量子算法、复杂性、测试和基准测试
  • 批准号:
    2311733
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Continuing Grant
Establishing and benchmarking advanced methods to comprehensively characterize somatic genome variation in single human cells
建立先进方法并对其进行基准测试,以全面表征单个人类细胞的体细胞基因组变异
  • 批准号:
    10662975
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
Collaborative Research: BeeHive: A Cross-Problem Benchmarking Framework for Network Biology
合作研究:BeeHive:网络生物学的跨问题基准框架
  • 批准号:
    2233968
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Continuing Grant
Benchmarking Quantum Advantage
量子优势基准测试
  • 批准号:
    EP/Y004418/1
  • 财政年份:
    2023
  • 资助金额:
    $ 139.76万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了